Skip to main content
. 2016 Nov 28;20(5):162–167.

Figure 1.

Figure 1.

Virologic success at 48 weeks (defined as HIV RNA below 50 copies/mL) according to baseline viral load (top) and CD4+ cell count (bottom) in studies comparing elvitegravir/cobicistat/emtricitabine/tenofovir (elvitegravir group) with efavirenz/emtricitabine/tenofovir (efavirenz group) or atazanavir/ritonavir plus tenofovir/emtricitabine (atazanavir group). Adapted with permission from Ward et al.9